Synapse - Works

Results (115781)

A phase 1a/b dose escalation study of the FLT3/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia

Meeting Abstract

Goldberg, A. D.; Ohanian, M.; Koller, P. B.; Cherry, M.; Altman, J. K.; Tomlinson, B.; Chandhok, N. S.; Haney, D. N.; Hu, J.; Sinha, R. K.; more...
Blood (2022)

Fulltext@MSK | Save

Molecular, epigenetic, and immune landscape of TP53-mutated (TP53-M) Acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS)

Meeting Abstract

Bewersdorf, J. P.; Hasle, V.; Shallis, R. M.; Thompson, E. G.; de Menezes, D. L.; Rose, S.; Boss, I. W.; Halene, S.; Haferlach, T.; Fox, B.; more...
Blood (2022)

Fulltext@MSK | Save

Intensive therapy for NPM1 mutant AML patients: Negative impact of FLT3-ITD(high)but not FLT3-ITD(low) and FLT3TKD and role of transplant in patients over 60 years of age

Meeting Abstract

Winer, E. S.; Flamand, Y.; Shallis, R. M.; Stempel, J. M.; Goldberg, A. D.; Stahl, M. F.; Patel, A. A.; Duvall, A. S.; Abaza, Y.; Oh, T. S.; more...
Blood (2022)

Fulltext@MSK | Save

Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukaemia

Meeting Abstract

Leongamornlert, D.; Gutiérrez-Abril, J.; Lee, S.; Barretta, E.; Creasey, T.; Alapi, K. Z.; Levine, M. F.; Arango-Ossa, J. E.; Medina-Martinez, J. S.; Kirkwood, A. A.; more...
Blood (2022)

Fulltext@MSK | Save

Clinical outcomes of patients with TP53-mutated AML after first relapse or with primary refractory disease: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND)

Meeting Abstract

Badar, T.; Atallah, E. L.; Saliba, A. N.; Shallis, R. M.; Stahl, M. F.; Bewersdorf, J. P.; Correia, G. S. D.; Patel, A. A.; Abaza, Y.; Murthy, G. S. G.; more...
Blood (2022)

Fulltext@MSK | Save

Entospletinib (ENTO) in combination with cytarabine (Ara-C) and daunorubicin (DNR) in newly diagnosed (ND) adult patients with NPM1-mutated and FLT3-ITD wild-type acute myeloid leukemia (AML) Is associated with good response and survival: A phase 2 sub-study of the beat AML master trial

Meeting Abstract

Borate, U.; Li, R.; Huang, Y.; Swords, R. T.; Traer, E.; Stein, E.; Foran, J. M.; Baer, M. R.; Duong, V. H.; Stock, W.; more...
Blood (2022)

Fulltext@MSK | Save

Arcch: Improving the performance of clonal hematopoiesis variant calling and interpretation using a consensus based approach

Meeting Abstract

Schmidt, E. L.; Chan, I. C. C.; Panchot, A.; Wiley, B.; Liu, J.; Moukarzel, L.; Zhang, Y. W.; Link, D. C.; Stopsack, K.; Bolton, K. L.
Blood (2022)

Fulltext@MSK | Save

OGDH Is a genetic vulnerability and therapeutic target in acute myeloid leukemia

Meeting Abstract

Millman, S. E.; Chaves-Perez, A.; Morris, J. P. 4th; Chen, C. C.; Ho, Y. J.; Raman, S. J.; Yashinskie, J. J.; Mezzadra, R.; Narendra, V.; Tian, S.; more...
Blood (2022)

Fulltext@MSK | Save

Epichaperome inhibition targets kinase and TP53 mutant therapy resistant AML

Meeting Abstract

Carter, B. Z.; Mak, P. Y.; Tao, W.; Ostermann, L. B.; Nishida, Y.; Pemmaraju, N.; Boettcher, S.; Shpall, E. J.; Chiosis, G.; Karras, G.; more...
Blood (2022)

Fulltext@MSK | Save

Effects of LSD1 inhibition with Img-7289 on the leukemia initiating cell population with induction of differentiation and cell death in pediatric relapsed/refractory AML

Meeting Abstract

Rosenzweig, J.; Coutinho, D. F.; Long, M.; Souto, K.; Sanchez, G. I.; Fishkin, R.; Guillan, K.; Siddiquee, A.; Calder, P.; You, D.; more...
Blood (2022)

Fulltext@MSK | Save